Neoadjuvant Therapy in Biliary Adenocarcinoma

• Status: Recruiting
• Trial end date: 2029-02-04
• Target enrollment: 0
• Participant gender: All

Summary

Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jordan Kharofa
• Treatments: Fluorouracil; Gemcitabine

Criteria

Inclusion Criteria:

• Age ≥18 years.

• ECOG performance status ≤2

• Patients must have adequate organ and marrow function as defined below:

leukocytes ≥3,000/mcL absolute neutrophil count ≥1,500/mcL platelets ≥100,000/mcL total bilirubin ≤ 7 AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2

• Known human immunodeficiency virus (HIV)-infected patients must be on effective anti-retroviral therapy with undetectable viral load within 6 months to be eligible for this trial.

• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

• Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

• Patients must have either biopsy proven biliary adenocarcinoma (Intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, extrahepatic cholangiocarcinoma), or Gallbladder Adenocarcinoma or cytology with FISH abnormality sufficient for diagnosis.

• Patients must be deemed to have tumor that is resectable by the surgical oncologist and must have no medical contraindications to surgery.

• All patients must have a CT scan of the chest, abdomen, and pelvis with contrast or PET scan demonstrating no evidence of metastatic disease within 6 weeks prior to protocol therapy.

• Patients with enlarged regional lymph nodes within the dissection basin are eligible for participation.

• Women of child-bearing potential and men must agree to use adequate contraception for 14 months (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 14 months after completion.

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients with metastatic disease on imaging (biopsy not required).

• Patients not eligible for surgery due to tumor anatomy or medical comorbidities.

• Patients with known hypersensitivity to cisplatin, gemcitabine or 5-FU or any component of the formulation.

• Patients who have had chemotherapy or radiotherapy within 3 months prior to entering the study.

• Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.

• Patients who are currently receiving any other investigational agents are excluded. Patients who received investigational agents prior to consenting to participate on this study who are no longer currently receiving those agents, are eligible.

• Patients with uncontrolled intercurrent illness that would prevent receipt of standard of care chemotherapy, radiation or surgery.

• Patients with psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant women are excluded from this study.